Trastuzumab biosimilar - BIOCND/Genor Biopharma

Drug Profile

Trastuzumab biosimilar - BIOCND/Genor Biopharma

Alternative Names: GB 221; Herceptin biosimilar - BIOCND/Genor Biopharma

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Genor Biopharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 02 Jan 2017 Phase-II clinical trials in Breast cancer in China (IV) (Genor Biopharma pipeline, December 2016)
  • 14 May 2015 Phase I development is ongoing in China and Australia
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top